Shanghai Pharma H1 2026 Revenue RMB147.47B, Net Profit Down 21.4%
Shanghai Pharmaceuticals reported H1 2026 revenue of RMB147.47 billion, up 4.15% year-on-year, while net profit attributable to shareholders fell 21.4% to RMB3.504 billion, mainly due to one-off special gains or losses. Excluding these items, net profit rose 1.65% to RMB2.828 billion. The company proposed a cash dividend of RMB1 per 10 shares.
Shanghai Pharmaceuticals has released its interim report for the first half of 2026. During the reporting period, the company achieved operating revenue of RMB147.47 billion, up 4.15% year-on-year. Net profit attributable to shareholders of the listed company stood at RMB3.504 billion, down 21.4% year-on-year. Basic earnings per share were RMB0.95. The company plans to distribute a cash dividend of RMB1 (tax inclusive) for every 10 shares.
The decline in net profit was mainly attributable to fluctuations in one-off special gains or losses. Excluding these items, net profit attributable to shareholders of the listed company was RMB2.828 billion, up 1.65% year-on-year. The pharmaceutical industrial segment generated sales revenue of RMB13.186 billion, up 8.44% year-on-year, while the pharmaceutical commercial segment recorded sales revenue of RMB134.283 billion, up 3.75% year-on-year.